- Home
- TONX vs ALDX Comparison
TONX vs ALDX Comparison
Compare TONX & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TONX | ALDX |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.4M | 293.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | TONX | ALDX |
|---|---|---|
| Price | $3.06 | $4.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 715.7K | ★ 850.7K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 7.29 | N/A |
| Revenue | ★ $7,760,000.00 | N/A |
| Revenue This Year | $526.82 | N/A |
| Revenue Next Year | $45.45 | $36.25 |
| P/E Ratio | $0.42 | ★ N/A |
| Revenue Growth | ★ 3760.70 | N/A |
| 52 Week Low | $2.73 | $1.14 |
| 52 Week High | $29.77 | $7.20 |
Technical Indicators
Market Signals| Indicator | TONX | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 40.60 |
| Support Level | N/A | $4.71 |
| Resistance Level | N/A | $5.68 |
| Average True Range (ATR) | 0.00 | 0.29 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 0.00 | 2.48 |
Price Performance
Historical ComparisonAbout TONX TON Strategy Company Common Stock
TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.